Breaking News

Alibaba Opens at $92.70 per Share, IPO Priced at $68
Tweet TWEET

Pacific Biosciences Introduces New Chemistry With Longer Read Lengths to Detect Novel Features in DNA Sequence and Advance

Pacific Biosciences Introduces New Chemistry With Longer Read Lengths to
Detect Novel Features in DNA Sequence and Advance Genome Studies of Large
Organisms

New Photo-Protected Fluorescent Dye Chemistry Boosts Average Read Lengths to
8,500 Bases, With Reads Exceeding 30,000 Bases

MENLO PARK, Calif., Oct. 3, 2013 (GLOBE NEWSWIRE) -- Pacific Biosciences of
California, Inc. (Nasdaq:PACB), provider of the PacBio^® RS II DNA Sequencing
System, today announced significant new product enhancements to support
researchers working on complex genome projects. The new P5 polymerase and C3
chemistry combination (P5-C3) extends the industry-leading sequence read
lengths to an average of approximately 8,500 bases, with the longest reads
exceeding 30,000 bases. A key feature of this performance enhancement is the
inclusion of new photo-protected dyes, used to distinguish the four DNA bases
using four colors of fluorescence. These photo-protected dyes shield the P5
polymerase from laser-induced damage, allowing the polymerase to provide
extremely long sequencing reads.

A complete genome sequence is an extremely valuable tool in many types of
scientific research, yet most organisms do not have their complete genome
assembled – including humans. Instead, complex genomes are partially completed
with difficult repetitive sections and longer structural variants excluded
from the assembly, resulting in highly fragmented, incomplete genomes. To
sequence the complete genome of an organism, very long sequencing reads are
required to span these regions, which can be critical in understanding gene
function. The very long sequence reads provided by the PacBio RS II Single
Molecule, Real-time (SMRT^®) sequencing system provide researchers the
opportunity to fill gaps or reduce the number of fragments in assemblies of
moderate and large genomes.

"With the P5-C3 release, we saw another step change in the evolution of PacBio
data," said Dr. Paul Coupland, Research Scientist at the Wellcome Trust Sanger
Institute, which served as a test site. "We obtained polymerase mean read
lengths of greater than 8,500 bases, enabling us to span longer repeats, phase
SNPs, and discover structural variants that were previously hidden. Our first
data set was used for hybrid de novo assembly, and when combined with existing
P4-C2 data the assembly was considerably improved."

"Following our steady stream of system and chemistry improvements during 2013,
including our v3 SMRT Cells, the PacBio RS II launch and the highly accurate
polymerase P4, this release is our next generation chemistry upon which future
developments and read length improvements will be built," said Kevin Corcoran,
Senior Vice President of Market Development for Pacific Biosciences. "Now 50%
of the bases come from reads over 10,000 bases in length, nearly doubling the
per-SMRT^® Cell throughput. As our customers continue to sequence larger and
more complex genomes, the long reads generated from P5-C3 chemistry make it an
ideal choice for scaffolding and hybrid de novo assemblies."

The latest release also includes 20,000-base size-selected library protocols
optimized for use with the Sage Science BluePippin™ DNA size selection system,
along with an upgraded version of SMRT Analysis (available at
http://pacbiodevnet.com/), which introduces an update to the popular HGAP
assembler. The new HGAP 2 assembler significantly decreases the time required
to perform de novo genome assembly. These HGAP performance enhancements also
extend the range of genome sizes that can be assembled. Additional software
features include diploid-aware SNP detection as well as haplotype phasing of
amplicons, which provides users the opportunity to utilize the platform for
applications such as HLA analysis. The new reagents are available in addition
to the previously released P4-C2 chemistry, which is still recommended for
PacBio-only de novo assembly, minor-variant detection, targeted sequencing,
and cDNA applications.

Researchers attending the 2013 American Society of Human Genetics annual
meeting in Boston can attend a workshop on October 24 from 12:30-2:00 p.m. to
learn more about the PacBio RS II and hear from customers who are using the
system.

More information about the PacBio RS II and the latest product enhancements is
available at: www.pacb.com.

About Pacific Biosciences

Pacific Biosciences of California, Inc. (Nasdaq:PACB) offers the PacBio^® RS
II DNA Sequencing System to help scientists solve genetically complex
problems. Based on its novel Single Molecule, Real-Time (SMRT^®) technology,
the company's products enable: targeted sequencing to more comprehensively
characterize genetic variations; de novo genome assembly to more fully
identify, annotate and decipher genomic structures; and DNA base modification
identification to help characterize epigenetic regulation and DNA damage. By
providing access to information that was previously inaccessible, Pacific
Biosciences enables scientists to increase their understanding of biological
systems. More information is available at www.pacb.com.

Forward Looking Statements

This press release contains forward-looking statements relating to the current
or future performance of products and product enhancements. You should not
place undue reliance on these forward-looking statements because they involve
known and unknown risks, uncertainties and other factors that are, in some
cases, beyond the Company's control and that could materially affect actual
results. Factors that could materially affect actual results can be found in
the Company's filings with theSecurities and Exchange Commission, including
the most recently filed Quarterly Report on Form 10-Q, and include those
listed under the caption "Risk Factors." The Company expressly disclaims any
intent or obligation to update these forward-looking statements, except as
required by law.

CONTACT: For Pacific Biosciences:
        
         Media:
         Maurissa Messier
         For Pacific Biosciences
         760.539.7417
         maurissa@bioscribe.com
        
         Investors:
         Trevin Rard
         Pacific Biosciences
         650.521.8450
         ir@pacificbiosciences.com
 
Press spacebar to pause and continue. Press esc to stop.